

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.


As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

What is claimed is:

1. A compound having the structure:



wherein A is



wherein each of Y_1 , Y_2 , Y_3 , Y_4 and Y_5 is independently -H; straight chained or branched C_1 - C_7 alkyl, monofluoroalkyl or polyfluoroalkyl;

straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_3$, $-OCOR_3$, $-COR_3$, $-CONHR_3$, $-CON(R_3)_2$, or $-COOR_3$; or any two of Y_1 , Y_2 , Y_3 , Y_4 and Y_5 present on adjacent carbon atoms can constitute a methylenedioxy group;

wherein X is S; O; or NR_3 ;

wherein R_1 is -H; $-NO_2$; -CN; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; $-N(R_3)_2$; $-OR_3$; $-(CH_2)_pOR_3$; $-COR_3$; $-CO_2R_3$; or $-CON(R_3)_2$;


wherein R_2 is -H; straight chained or branched C_1-C_7 alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; C_3-C_{10} cycloalkyl- C_1-C_{10} -alkyl, C_3-C_{10} cycloalkyl- C_1-C_{10} -monofluoroalkyl or C_3-C_{10} cycloalkyl- C_1-C_{10} -polyfluoroalkyl; -CN; $-CH_2XR_3$, $-CH_2X(CH_2)_pNHR_3$, $-(CH_2)_nNHR_3$, $-CH_2X(CH_2)_pN(R_3)_2$, $-CH_2X(CH_2)_pN_3$, or $-CH_2X(CH_2)_pNHCXR_7$; or $-OR_3$;

wherein each p is independently an integer from 1 to 7; wherein each n is independently an integer from 0 to 5;

wherein each R_3 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7

alkenyl or alkynyl; C₃-C₇ cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;

5 wherein R₄ is



15

wherein Z' is (CH₂)_o, CO, (CH₂)_oCO, or CO(CH₂)_o;

wherein each V is independently O; S; CH₂; CR₅R₇; C(R₇)₂; or NR₇;

20

wherein each m is independently an integer from 0 to 3; wherein o is an integer from 1 to 3;

25

wherein each R is independently -H; -F; straight chained or branched C₁-C₇ alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C₂-C₇ alkenyl or alkynyl; -N(R₃)₂; -NO₂; -CN; -CO₂R₃; or -OR₃;

30

wherein R₅ and R₇ each independently may be -H; F; Cl; Br; I; -COR₃; -CO₂R₃; -CON(R₃)₂; -CN; -NO₂; -N(R₃)₂; -OR₃; -SR₃; -(CH₂)_pOR₃; -(CH₂)_pSR₃; straight

35


chained or branched C₁-C₇ alkyl, aminoalkyl, carboxamidoalkyl; straight chained or branched C₂-C₇ alkenyl or alkynyl, or C₃-C₇ cycloalkyl or cycloalkenyl; wherein the alkyl, aminoalkyl, carboxamidoalkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl may be substituted with one or more aryl or heteroaryl, wherein the aryl or heteroaryl

may be substituted with -F, -Cl, -Br, -I, -NO₂, -CN, -OR₃, -SR₃, C₁-C₃ alkyl, or carboxamido; aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with one or more -F, -Cl, -Br, -I, COR₃, CO₂R₃, -CON(R₃)₂, -CN, -NO₂, -N(R₃)₂, -OR₃, -SR₃, (CH₂)₆OR₃, (CH₂)₆SR₃; straight chained or branched C₁-C₇ alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C₂-C₇ alkenyl, C₂-C₇ alkynyl, C₃-C₇ cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; and

wherein each R₆ is independently -H; straight chained or branched C₁-C₇ alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C₂-C₇ alkenyl or alkynyl; C₃-C₇ cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; or -OR₃;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein the compound comprises the (+) enantiomer.
3. The compound of claim 1, wherein the compound comprises the (-) enantiomer.
4. The compound of claim 1 having the structure:




5

10

5. The compound of claim 4, wherein Z' is CO and n is 0.

6. The compound of claim 5 having the structure:


15



20

7. A compound selected from the group consisting of:


25



30


35

5




10

15




20

25




30

35




5




10

and


15



8. A compound having the structure:



wherein A is



wherein each of Y_1 , Y_2 , Y_3 , Y_4 and Y_5 is independently -H; straight chained or branched C_1 - C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2 - C_7 alkenyl or

alkynyl; C₃-C₇ cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -F, -Cl, -Br, or -I; -NO₂; -N₃; -CN; -OR₃, -OCOR₃, -COR₃, -CONHR₃, -CON(R₃)₂, or -COOR₃; or any two of Y₁, Y₂, Y₃, Y₄ and Y₅ present on adjacent carbon atoms can constitute a methylenedioxy group;

wherein X is S; O; or NR₃;

wherein R₁ is -H; -NO₂; -CN; straight chained or branched C₁-C₇ alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C₂-C₇ alkenyl or alkynyl; C₃-C₇ cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R₃)₂; -OR₃; -(CH₂)_pOR₃; -COR₃; -CO₂R₃; or -CON(R₃)₂;

wherein R₂ is -H; straight chained or branched C₁-C₇ alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C₂-C₇ alkenyl or alkynyl; C₃-C₇ cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; C₃-C₁₀ cycloalkyl-C₁-C₁₀-alkyl, C₃-C₁₀ cycloalkyl-C₁-C₁₀-monofluoroalkyl or C₃-C₁₀ cycloalkyl-C₁-C₁₀-polyfluoroalkyl; -CN; -CH₂XR₃, -CH₂X(CH₂)_pNHR₃, -(CH₂)_nNHR₃, -CH₂X(CH₂)_pN(R₃)₂, -CH₂X(CH₂)_pN₃, or -CH₂X(CH₂)_pNHCXR₇; or -OR₃;

wherein each p is independently an integer from 1 to 7; wherein each n is independently an integer from 0 to 5;

wherein each R₃ is independently -H; straight chained or branched C₁-C₇ alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C₂-C₇ alkenyl or alkynyl; C₃-C₇ cycloalkyl,

monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;

wherein R_4 is

5

10





15

20

25


30

35




5

10




15




20


25




30



35




5



10

or



15

20

wherein Z is C₂-C₇ alkenyl or alkynyl; CH₂; O; CO; CO₂; CONR₃; S; SO; SO₂; or NR₃;

25

wherein Z' is (CH₂)₀, CO, (CH₂)₀CO, or CO(CH₂)₀;

wherein each D is independently CH₂; O; S; NR₃; CO; or CS;

30

wherein W is C=O; C=NOR₃; substituted or unsubstituted phenyl, pyridyl, thiophenyl, furanyl, pyrazinyl, pyrrol, naphthyl, indolyl, imidazolyl, benzfurazanyl, benzfuranyl or benzyimidazolyl, wherein the phenyl, pyridyl, thiophenyl, furanyl, pyrazinyl, pyrrol, naphthyl, indolyl, imidazolyl, benzfurazanyl, benzfuranyl or benzyimidazolyl is substituted with -H, -F, -Cl, -

35

Br, -I, -NO₂, -CN, straight chained or branched C₁-C₇ alkyl, straight chained or branched C₁-C₇ monofluoroalkyl, straight chained or branched C₁-C₇ polyfluoroalkyl, straight chained or branched C₂-C₇ alkenyl, straight chained or branched C₂-C₇ alkynyl, C₃-C₇ cycloalkyl, C₃-C₇ monofluorocycloalkyl, C₃-C₇ polyfluorocycloalkyl, C₃-C₇ cycloalkenyl, -N(R₃)₂, -OR₃, -COR₃, -CO₂R₃, or -CON(R₃)₂;

wherein each V is independently O; S; CH₂; CR₅R₇; C(R₇)₂; or NR₇;

wherein each m is independently an integer from 0 to 3; wherein o is an integer from 1 to 3;

wherein each R is independently -H; -F; straight chained or branched C₁-C₇ alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C₂-C₇ alkenyl or alkynyl; -N(R₃)₂; -NO₂; -CN; -CO₂R₃; or -OR₃;

wherein R₅ is aryl or heteroaryl substituted with one or more of F; Cl; Br; I; COR₃; CO₂R₃; -CON(R₃)₂; CN; -NO₂; -N(R₃)₂; -OR₃, -SR₃; (CH₂)_oOR₃; (CH₂)_oSR₃; straight chained or branched C₁-C₇ alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C₂-C₇ alkenyl, C₂-C₇ alkynyl, C₃-C₇ cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;


wherein each R₆ is independently -H; straight chained or branched C₁-C₇ alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C₂-C₇ alkenyl or alkynyl; C₃-C₇ cycloalkyl,

monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; or -OR₃;

5 wherein R₇ is aryl or heteroaryl substituted with one or more of F; Cl; Br; I; COR₃; CO₂R₃; -CON(R₃)₂; CN; -NO₂; -N(R₃)₂; -OR₃, -SR₃; (CH₂)₆OR₃; (CH₂)₆SR₃; straight chained or branched C₁-C₇ alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched
10 C₂-C₇ alkenyl, C₂-C₇ alkynyl, C₃-C₇ cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; and


15 wherein R₈ is -H; substituted or unsubstituted benzyl, benzoyl, phenyl, pyridyl, thiophenyl, furanyl, pyrazinyl, pyrrolyl, naphthyl, indolyl, imidazolyl, benzfurazanyl, benzfuranyl, benzimidazolyl or 2-keto-1-benzimidazolyl, wherein the benzyl, benzoyl, phenyl, pyridyl,
20 thiophenyl, furanyl, pyrazinyl, pyrrolyl, naphthyl, indolyl, imidazolyl, benzfurazanyl, benzfuranyl, benzimidazolyl or 2-keto-1-benzimidazolyl is substituted with -H, -F, -Cl, -Br, -I, -NO₂, -CN, straight chained or branched C₁-C₇ alkyl, straight
25 chained or branched C₁-C₇ monofluoroalkyl, straight chained or branched C₁-C₇ polyfluoroalkyl, straight chained or branched C₂-C₇ alkenyl, straight chained or branched C₂-C₇ alkynyl, C₃-C₇ cycloalkyl, C₃-C₇ monofluorocycloalkyl, C₃-C₇ polyfluorocycloalkyl,
30 C₃-C₇ cycloalkenyl, -N(R₃)₂, -OR₃, -COR₃, -CO₂R₃, or -CON(R₃)₂; substituted or unsubstituted straight chained or branched C₁-C₇ alkyl, monofluoroalkyl or polyfluoroalkyl; substituted or unsubstituted straight chained or branched C₂-C₇ alkenyl or
35 alkynyl; C₃-C₇ cycloalkyl or cycloalkenyl, wherein the alkyl, monofluoroalkyl, polyfluoroalkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl is

substituted with -H, phenyl, pyridyl, thiophenyl, furanyl, pyrazinyl, pyrrol, naphthyl, indolyl, imidazolyl, benzfurazanyl, benzfuranyl, benzimidazolyl, $-N(R_3)_2$, $-NO_2$, $-CN$, $-CO_2R_3$, $-OR_3$;




or a pharmaceutically acceptable salt thereof.

9. The compound of claim 8 having the structure:




10. The compound of claim 9 having the structure:



11. The compound of claim 10 having the structure:

5

10




15

wherein V is selected from CR_5R_7 or NR_7 and p is selected from 1-3.


12. The compound of claim 11, wherein the compound is selected from the group consisting of:

20



25

30




35


and

5


10



13. A compound having the structure:



wherein A is



wherein each of Y_1 , Y_2 , Y_3 , Y_4 and Y_5 is independently -H; straight chained or branched C_1 - C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2 - C_7 alkenyl or alkynyl; C_3 - C_7 cycloalkyl, monofluorocycloalkyl,

B'
cont 5

polyfluorocycloalkyl or cycloalkenyl; -F, -Cl, -Br, or -I; -NO₂; -N₃; -CN; -OR₄, -OCOR₄, -COR₄, -CONHR₄, -CON(R₄)₂, or -COOR₄; or any two of Y₁, Y₂, Y₃, Y₄ and Y₅ present on adjacent carbon atoms can constitute a methylenedioxy group;

wherein X is S; O; or NR₄;





10 wherein B is -H; straight chained or branched C₁-C₇ alkyl, monofluoroalkyl, polyfluoroalkyl, alkoxy or thioalkyl; straight chained or branched C₂-C₇ alkenyl; -SCH₂C₆H₄OR₄; -(CH₂)_nC₆H₅; -CH₂X(CH₂)_nNHR₄; -(CH₂)_nNHR₄; or -OR₄;

15 wherein R₁ is -H; -NO₂; -CN; straight chained or
branched C₁-C₇ alkyl, monofluoroalkyl or
polyfluoroalkyl; straight chained or branched C₂-C₇
alkenyl or alkynyl; C₃-C₇ cycloalkyl,
monofluorocycloalkyl, polyfluorocycloalkyl or
20 cycloalkenyl; -N(R₄)₂; -OR₄; -(CH₂)_pOR₄; -COR₄; -
CO₂R₄; or -CON(R₄)₂;

wherein R_2 is -H; straight chained or branched C_1 - C_7 alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2 - C_7 alkenyl or alkynyl; C_3 - C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; C_3 - C_{10} cycloalkyl- C_1 - C_{10} -alkyl, C_3 - C_{10} cycloalkyl- C_1 - C_{10} -monofluoroalkyl or C_3 - C_{10} cycloalkyl- C_1 - C_{10} -polyfluoroalkyl; -CN; $-CH_2XR_4$, $-CH_2X(CH_2)_pNHR_4$, $-(CH_2)_pNHR_4$, $-CH_2X(CH_2)_pN(R_4)_2$, $-CH_2X(CH_2)_pN_3$, or $-CH_2X(CH_2)_pNHCXR_7$; or $-OR_4$;

35 wherein each p is independently an integer from 1 to 7; wherein each n is independently an integer from 0 to 5;

wherein R_3 is



B'
cont

5

10

15

20


25

30


35

B' cont

5




10




15

20





25




30

35



or



wherein Z is C₂-C₇ alkenyl or alkynyl; CH₂; O; CO; CO₂; CONR₄; S; SO; SO₂; or NR₄;

wherein Z' is (CH₂)₀, CO, (CH₂)₀CO, or CO(CH₂)₀;

wherein each D is independently CH₂; O; S; NR₄; CO; or CS;

wherein W is C=O; C=NOR₄; substituted or unsubstituted phenyl, pyridyl, thiophenyl, furanyl, pyrazinyl, pyrrol, naphthyl, indolyl, imidazolyl, benzfurazanyl, benzfuranyl or benzyimidazolyl, wherein the phenyl, pyridyl, thiophenyl, furanyl, pyrazinyl, pyrrol, naphthyl, indolyl, imidazolyl, benzfurazanyl, benzfuranyl or

5

10

15

20

25

30

35

monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;

wherein each R_6 is independently -H; straight chained or branched C_1-C_7 alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; or $-OR_4$;

wherein R_7 is aryl or heteroaryl substituted with one or more of F; Cl; Br; I; COR_3 ; CO_2R_3 ; $-CON(R_3)_2$; CN; $-NO_2$; $-N(R_3)_2$; $-OR_3$, $-SR_3$; $(CH_2)_6OR_3$; $(CH_2)_6SR_3$; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C_2-C_7 alkenyl, C_2-C_7 alkynyl, C_3-C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; and


wherein R_8 is -H; substituted or unsubstituted benzyl, benzoyl, phenyl, pyridyl, thiophenyl, furanyl, pyrazinyl, pyrrol, naphthyl, indolyl, imidazolyl, benzfurazanyl, benzfuranyl, benzimidazolyl or 2-keto-1-benzimidazolyl, wherein the benzyl, benzoyl, phenyl, pyridyl, thiophenyl, furanyl, pyrazinyl, pyrrol, naphthyl, indolyl, imidazolyl, benzfurazanyl, benzfuranyl, benzimidazolyl or 2-keto-1-benzimidazolyl is substituted with -H, -F, -Cl, -Br, -I, $-NO_2$, -CN, straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_3-C_7 cycloalkyl, C_3-C_7 monofluorocycloalkyl, C_3-C_7 polyfluorocycloalkyl,

B'
cont

5

10

C_3-C_7 cycloalkenyl, $-N(R_4)_2$, $-OR_4$, $-COR_4$, $-CO_2R_4$, or $-CON(R_4)_2$; substituted or unsubstituted straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; substituted or unsubstituted straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or cycloalkenyl, wherein the alkyl, monofluoroalkyl, polyfluoroalkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl is substituted with $-H$, phenyl, pyridyl, thiophenyl, furanyl, pyrazinyl, pyrrol, naphthyl, indolyl, imidazolyl, benzfurazanyl, benzfuranyl, benzimidazolyl, $-N(R_4)_2$, $-NO_2$, $-CN$, $-CO_2R_4$, $-OR_4$;




or a pharmaceutically acceptable salt thereof.

15

D'
cont

20


14. The compound of claim 13, wherein the compound comprises the (-) enantiomer.
15. The compound of claim 13, wherein the compound comprises the (+) enantiomer.
16. The compound of claim 13 having the structure:




30

Sub
B²


17. The compound of claim 16 having the structure:




18. The compound of claim 17, wherein the compound is selected from the group consisting of:




and



19. A compound having the structure:



wherein A is



35

wherein each of Y_1 , Y_2 , Y_3 , Y_4 and Y_5 is independently -H; straight chained or branched C_1 - C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2 - C_7 alkenyl or alkynyl; C_3 - C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -F, -Cl,

*D¹
cont⁵*

~~-Br, or -I; -NO₂; -N₃; -CN; -OR₄, -OCOR₄, -COR₄,
-CONHR₄, -CON(R₄)₂, or -COOR₄; or any two of Y₁, Y₂,
Y₃, Y₄ and Y₅ present on adjacent carbon atoms can
constitute a methylenedioxy group;~~

~~wherein X is S; O; or NR₄;~~

~~wherein B is -H; straight chained or branched C₁-C₇
alkyl, monofluoroalkyl, polyfluoroalkyl, alkoxy or
thioalkyl; straight chained or branched C₂-C₇
alkenyl; -SCH₂C₆H₄OR₄; -(CH₂)₆C₆H₅; -CH₂X(CH₂)_nNHR₄;
-(CH₂)_nNHR₄; or -OR₄;~~


~~wherein R₁ is -H; -NO₂; -CN; straight chained or
branched C₁-C₇ alkyl, monofluoroalkyl or
polyfluoroalkyl; straight chained or branched C₂-C₇
alkenyl or alkynyl; C₃-C₇ cycloalkyl,
monofluorocycloalkyl, polyfluorocycloalkyl or
cycloalkenyl; -N(R₄)₂; -OR₄; -(CH₂)_pOR₄; -COR₄; -
CO₂R₄; or -CON(R₄)₂;~~

~~wherein R₂ is -H; straight chained or branched C₁-C₇
alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl,
monofluoroalkyl or polyfluoroalkyl; straight
chained or branched C₂-C₇ alkenyl or alkynyl; C₃-C₇
cycloalkyl, monofluorocycloalkyl,
polyfluorocycloalkyl or cycloalkenyl; C₃-C₁₀
cycloalkyl-C₁-C₁₀-alkyl, C₃-C₁₀ cycloalkyl-C₁-C₁₀-
monofluoroalkyl or C₃-C₁₀ cycloalkyl-C₁-C₁₀-
polyfluoroalkyl; -CN; -CH₂XR₄, -CH₂X(CH₂)_pNHR₄,
-(CH₂)_nNHR₄, -CH₂X(CH₂)_pN(R₄)₂, -CH₂X(CH₂)_pN₃, or
-CH₂X(CH₂)_pNHCXR₇; or -OR₄;~~

~~wherein each p is independently an integer from 1
to 7; wherein each n is independently an integer
from 0 to 5;
wherein R₃ is~~

D1
cont

5



10

wherein Z' is $(CH_2)_o$, CO , $(CH_2)_oCO$, or $CO(CH_2)_o$;

15

wherein each V is independently O ; S ; CH_2 ; CR_5R_7 ; $C(R_7)_2$; or NR_7 ;

20

wherein each m is independently an integer from 0 to 3; wherein o is an integer from 1 to 3;

25

wherein each R is independently $-H$; $-F$; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; $-N(R_4)_2$; $-NO_2$; $-CN$; $-CO_2R_4$; or $-OR_4$;

30

wherein each R_4 is independently $-H$; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;

35

wherein R_5 and R_7 each independently may be $-H$; F ; Cl ; Br ; I ; $-COR_3$; $-CO_2R_3$; $-CON(R_3)_2$; $-CN$; $-NO_2$; $-N(R_3)_2$; $-OR_3$; $-SR_3$; $-(CH_2)_pOR_3$; $-(CH_2)_pSR_3$; straight chained or branched C_1-C_7 alkyl, aminoalkyl,

D1
Cont

5

10

15

20

25

carboxamidoalkyl; straight chained or branched C₂-C₇ alkenyl or alkynyl, or C₃-C₇ cycloalkyl or cycloalkenyl; wherein the alkyl, aminoalkyl, carboxamidoalkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl may be substituted with one or more aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with -F, -Cl, -Br, -I, -NO₂, -CN, -OR₃, -SR₃, C₁-C₃ alkyl, or carboxamido; aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with one or more -F, -Cl, -Br, -I, COR₃, CO₂R₃, -CON(R₃)₂, -CN, -NO₂, -N(R₃)₂, -OR₃, -SR₃, (CH₂)₆OR₃, (CH₂)₆SR₃; straight chained or branched C₁-C₇ alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C₂-C₇ alkenyl, C₂-C₇ alkynyl, C₃-C₇ cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; and

wherein each R₆ is independently -H; straight chained or branched C₁-C₇ alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C₂-C₇ alkenyl or alkynyl; C₃-C₇ cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; or -OR₄;

or a pharmaceutically acceptable salt thereof.

Sub
A2

30

20. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.

D1
Cont

35

21. The pharmaceutical composition of claim 20 wherein the amount of the compound is an amount from about 0.01 mg to about 500 mg.

D1
cont

22. The pharmaceutical composition of claim 21 wherein the amount of the compound is from about 0.1 mg to about 60 mg.

5 23. The pharmaceutical composition of claim 22 wherein the amount of the compound is from about 1 mg to about 20 mg.

10 24. The pharmaceutical composition of claim 20, wherein the carrier is a liquid and the composition is a solution.

D1
cont

15 25. The pharmaceutical composition of claim 20, wherein the carrier is a solid and the composition is a tablet.

26. The pharmaceutical composition of claim 20, wherein the carrier is a gel and the composition is a suppository.

20 27. The pharmaceutical composition of claim 20, wherein the compound additionally does not cause a fall in blood pressure at dosages effective to alleviate benign prostatic hyperplasia.

25 28. A method of treating a subject suffering from benign prostatic hyperplasia which comprises administering to the subject an amount of the compound of claim 1 effective to treat benign prostatic hyperplasia.

D1
cont

35 29. A method of claim 28, wherein the compound additionally does not cause a fall in blood pressure at dosages effective to alleviate benign prostatic hyperplasia.

30. The method of claim 29, wherein the compound

effects treatment of benign prostatic hyperplasia by relaxing lower urinary tract tissue.

19
Cont

5

31. The method of claim 30, wherein lower urinary tract tissue is prostatic smooth muscle.

10

32. A method of treating a subject suffering from high intraocular pressure which comprises administering to the subject an amount of the compound of claim 1 effective to lower intraocular pressure.

15

33. A method of treating a subject suffering from a disorder associated with high cholesterol which comprises administering to the subject an amount of the compound of claim 1 effective to inhibit cholesterol synthesis.

20

34. A method of treating a disease which is susceptible to treatment by antagonism of the α_{1A} receptor which comprises administering to the subject an amount of the compound of claim 1 effective to treat the disease.

25

35. A method of treating a subject suffering from impotency which comprises administering to the subject an amount of the compound of claim 1 effective to treat impotency.

30

36. A method of treating a subject suffering from sympathetically mediated pain which comprises administering to the subject an amount of the compound of claim 1 effective to treat sympathetically mediated pain.

35

37. A method of treating a subject suffering from cardiac arrhythmia which comprises administering to the subject an amount of the compound of claim

1 effective to treat cardiac arrhythmia.

38. A method of treating a subject suffering from benign prostatic hyperplasia which comprises administering to the subject an amount of the compound of claim 1 effective to treat benign prostatic hyperplasia.

39. The method of claim 38, wherein the compound effects treatment of benign prostatic hyperplasia by relaxing lower urinary tract tissue.

40. The method of claim 39, wherein lower urinary tract tissue is prostatic smooth muscle.

41. A method of treating a subject suffering from benign prostatic hyperplasia which comprises administering to the subject an amount of the compound of claim 1 in combination with a 5 alpha-reductase inhibitor effective to treat benign prostatic hyperplasia.

42. The method of claim 41, wherein the 5-alpha reductase inhibitor is finasteride.

43. A method of treating a subject suffering from benign prostatic hyperplasia which comprises administering to the subject an amount of the compound of claim 1 in combination with a 5 alpha-reductase inhibitor effective to treat benign prostatic hyperplasia.

44. The method of claim 43, wherein the 5-alpha reductase inhibitor is finasteride.

45. A pharmaceutical composition comprising a therapeutically effective amount of the compound

Sub
4
A

Sub
A^s

Sub
AS
cont

of claim 1 in combination with a therapeutically effective amount of finasteride and a pharmaceutically acceptable carrier.

- 5 46. The pharmaceutical composition of claim 45 wherein the compound is present in an amount from about 0.01 mg to about 500 mg and the therapeutically effective amount of the finasteride is about 5 mg.
- 10 47. The pharmaceutical composition of claim 46 wherein the compound is present in an amount from about 0.1 mg to about 60 mg and the therapeutically effective amount of finasteride is about 5 mg.
- 15 48. The pharmaceutical composition of claim 47 wherein the compound is present in an amount from about 1 mg to about 20 mg and the therapeutically effective amount of finasteride is about 5 mg.
- 20 49. A method of relaxing lower urinary tract tissue which comprises contacting the lower urinary tract tissue with an amount of the compound of claim 1 effective to relax lower urinary tract tissue.
- 25 50. The method of claim 49, wherein the lower urinary tract tissue is prostatic smooth muscle.
- 30 51. A method of relaxing lower urinary tract tissue in a subject which comprises administering to the subject an amount of the compound of claim 1 effective to relax lower urinary tract tissue.
52. The method of claim 51, wherein the lower urinary tract tissue is prostatic smooth muscle.

Add
B3